Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acid Ceramidase Inhibition Disrupts Ceramide Homeostasis and Induces Mitochondrial Apoptosis in IDH1-Mutant Oligodendroglioma.

Research square·2026
Same author

Alkaline Bromodeoxyuridine (BrdU) Comet Assay to Detect Replication-Associated DNA Damage.

Current protocols·2025
Same author

Cancer Metabolism Meets DNA Repair: The Hidden Link to Therapy Resistance.

BioEssays : news and reviews in molecular, cellular and developmental biology·2025
Same author

miR-25-3p Modulates Tumor Aggressiveness and Ferroptosis Escape in T24 Bladder Cancer Cells In Vitro.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

mtKO: A dedicated guide RNA library for mitochondria research.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA-Alkylating Agents in Glioma.

Molecular cancer therapeutics·2025

Related Experiment Video

Updated: Jun 1, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics.

Fengchao Lang1, Karambir Kaur1, Javeria Zaheer1

  • 1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 17, 2025
PubMed
Summary

Cancer cells rely on the G2-M checkpoint for survival, making protein kinase, membrane-associated tyrosine/threonine 1 a promising target. Targeting this molecule may overcome therapy resistance and halt cancer progression.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Related Experiment Videos

Last Updated: Jun 1, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Cell-cycle checkpoints are critical for regulating cell division and preventing errors.
  • Cancer cells often exploit the G2-M checkpoint for DNA repair, contributing to therapy resistance and disease progression.
  • Targeting the G2-M checkpoint is a validated strategy in cancer therapy, with several agents in clinical trials.

Purpose of the Study:

  • To review recent advancements in targeting protein kinase, membrane-associated tyrosine/threonine 1 (a key G2-M checkpoint regulator).
  • To discuss the therapeutic potential of targeting this molecule in various cancer types.
  • To identify challenges and limitations for the clinical application of targeting protein kinase, membrane-associated tyrosine/threonine 1.

Main Methods:

  • Review of recent genome-scale functional genomic studies.
  • Summary of molecular targeting strategies for protein kinase, membrane-associated tyrosine/threonine 1.
  • Analysis of existing clinical data and research findings.

Main Results:

  • Protein kinase, membrane-associated tyrosine/threonine 1 has emerged as a crucial, yet previously underappreciated, G2-M checkpoint component.
  • This molecule shows promise as a therapeutic target across multiple cancer types.
  • The dependency of cancer cells on this checkpoint creates a vulnerability that can be exploited.

Conclusions:

  • Protein kinase, membrane-associated tyrosine/threonine 1 represents a significant target for novel cancer therapies.
  • Further research is needed to overcome challenges and expand the clinical utility of targeting this molecule.
  • Targeting this pathway holds potential for improving treatment outcomes in cancers exhibiting G2-M checkpoint dependency.